Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results
Tweet Send to a Friend
Brean Capital reiterated a Buy rating on Heron Therapeutics (NASDAQ: HRTX), and raised the price target to $55.00 (from $45.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
